Showing posts with label chemotherapy. Show all posts
Showing posts with label chemotherapy. Show all posts

Sunday, March 3, 2013

Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma.

2013 Feb

Source

Gynaecological Oncology Division, Department of Surgical Oncology, Tata Memorial Centre, Dr Ernest Borges Marg, Parel, Mumbai, India, 400012.

Abstract

BACKGROUND:

Ovarian carcinosarcoma, also known as malignant mixed Mullerian tumour, is a rare malignant gynaecological tumour constituting about 1% or less of all ovarian cancers. In over 80% of cases, there is extra-ovarian intra-abdominal spread at diagnosis. The primary treatment has traditionally been surgical cytoreduction followed by radiotherapy and chemotherapy or chemotherapy alone. Regimes have included cisplatin alone; a combination of doxorubicin, ifosfamide, dacarbazine, cyclophosphamide, taxol; and various other combinations. The effectiveness of these various regimens appears to be mixed. Therefore, there is a need to clarify if there is an optimum neoadjuvant or adjuvant therapy after surgical cytoreduction for this rare tumour. Also, it is important to address quality of life (QoL) issues related to treatment, particularly toxicity, as the overall prognosis appears to be poor.

OBJECTIVES:

To assess the effectiveness and safety of various adjuvant and neoadjuvant chemotherapy and radiotherapy options or chemotherapy alone in combination with surgery in the management of ovarian carcinosarcoma.

SEARCH METHODS:

We searched the Cochrane Gynaecological Cancer Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE up to February 2012. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of review articles and contacted experts in the field.

SELECTION CRITERIA:

We searched for randomised controlled trials (RCTs) that compared neoadjuvant or adjuvant chemotherapy and radiotherapy, or chemotherapy alone, in women with ovarian carcinosarcoma (malignant mixed Mullerian sarcoma of the ovary). We also reviewed non-randomised studies (NRS) for discussion in the absence of RCTs.

DATA COLLECTION AND ANALYSIS:

Two review authors independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found and therefore no data were analysed.

MAIN RESULTS:

The search strategy identified 297 unique references of which all were excluded.

AUTHORS' CONCLUSIONS:

We found no evidence to inform decisions about neoadjuvant and adjuvant chemotherapy and radiotherapy regimens, or chemotherapy alone, for women with ovarian carcinosarcoma. Ideally, an RCT that is multicentre or multinational, or well designed non-randomised studies that use multivariate analysis to adjust for baseline imbalances, are needed to compare treatment modalities and improve current knowledge. Further research in genetic and molecular signalling pathways might improve understanding of this tumour subtype.

Friday, February 8, 2013

Targeted anti-vascular therapies for ovarian cancer: current evidence.


Targeted anti-vascular therapies for ovarian cancer: current evidence.


Feb 2013

Source

Department of Medical Oncology, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.
Abstract
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer-angiogenesis.

Sunday, January 6, 2013

Paulinda Schimmel Babbini: Raising ovarian cancer awareness


Paulinda Schimmel Babbini: Raising ovarian cancer awareness




Often, when someone is coping with an extraordinary loss, the feelings can be all-encompassing. When Paulinda Schimmel Babbini’s daughter, Robin, died of ovarian cancer at the age of 20, instead of letting the tragic death immobilize her, Babbini made it her mission that no one else should go through what she had.

Babbini is the founder and president of The Ovarian Cancer Circle, a foundation she started in 2010 in memory of her daughter. In 2004, Robin, at age 16, was homecoming queen and co-captain of the cheerleading squad at Pacific Hills High School. That same year she also started complaining of cramps. Doctors brushed it off, saying it was her menstrual cycle. The symptoms persisted, however, and a year later she was diagnosed with stage-three ovarian cancer. Robin underwent a hysterectomy and chemotherapy treatments, and was able to enter into her first year of college at University of California, Santa Barbara. Six months later, the cancer recurred; she lost her tumultuous battle in 2006. 

Since its founding, the nonprofit Ovarian Cancer Circle, which includes 12 members, has raised more than $35,000 to fight ovarian cancer. 

“My focus for starting The Circle is to give ovarian cancer a higher public profile; to support research, educate, heighten awareness to the signs and symptoms of this cancer; and to raise funds for an early-detection test, which does not yet exist,” Babbini said. “So many lives are saved by mammograms, Pap smears and PSA tests [for prostate cancer]. But ovarian cancer is a stealth cancer, almost hidden, with few, and random, symptoms.” They are abdominal pressure, bloating, nausea, indigestion, feeling full but eating less, urinary frequency and constipation, she said. “Knowledge is critically important. I encourage women to pay attention to their bodies, know the symptoms and go to the gynecologist.”

Her group holds fundraisers twice a year and participates in numerous health fairs. They’ve hosted events at Hamburger Mary’s, featuring drag-queen bingo, along with a stand-up show at The Comedy Store in West Hollywood that showcased Sinbad as the headliner. On Feb. 21 at 11:30 a.m., Ovarian Cancer Circle is putting together a luncheon at Ruth’s Chris Steak House in Woodland Hills. The group will donate 100 percent of the proceeds to ovarian cancer research. On the Web site, theovariancancercircle.org, donations can be made by purchasing bracelets, scarves and necklaces in teal, the color designated to represent ovarian cancer, at Robin’s Store. 

Dalia Hayon, a friend, said she admires Paulinda for her strength and giving demeanor. “As a mother and grandmother, I would not have been able to bear the pain. It takes a special person and a mensch to be able to put aside her suffering, [to] be such an advocate for her girl and make sure other people are aware of it and know more about what to expect. She wasn’t expecting to get, but to give. She is a very giving person.”

For her part, Babbini said everything she does is in memory of her daughter. “Robin is my inspiration, motivation and strength. Her spirit inspires me to stay focused and, with steadfast determination, make a difference.”

Saturday, December 29, 2012

Nail toxicity associated with Paclitaxel treatment for ovarian cancer.


Nail toxicity associated with Paclitaxel treatment for ovarian cancer.


Jan 2103

Source

Park Nicollet Institute, St. Louis Park, MN.

Abstract


A 57-year-old woman named C. B. began experiencing abdominal pain and bloating. She presented to her primary physician with these symptoms, and her physician palpated an adenexal mass on pelvic examination. That prompted a computed tomography (CT) scan of the abdomen and pelvis, which demonstrated omental thickening as well as a mildly enlarged left ovary. After initial consultation with a gynecologic oncologist, C. B. was taken to surgery and a total abdominal hysterectomy bilateral salpingo-oophorectomy omentectomy partial bowel resection, and pelvic and periaortic lymph node dissection were performed. C. B. was diagnosed with stage IV ovarian cancer involving the omentum, pelvic lymph nodes, and bowel wall and was subsequently referred for postoperative chemotherapy.

Tuesday, December 25, 2012

Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage: A Randomized Controlled Trial.


Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage: A Randomized Controlled Trial.


Jan 2013

Source

Al-Banoon Fertility Centre, the Departments of Obstetrics and Gynecology and Clinical Oncology, Zagazig University School of Medicine, Zagazig, the Department of Medical Oncology, National Cancer Institute, Cairo University School of Medicine, Cairo, and the Department of Obstetrics and Gynecology, Alexandria University School of Medicine, and the Alexandria Regional Centre for Women's Health, Alexandria, Egypt; and the George and Fay Yee Centre for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.

Abstract


OBJECTIVE: To estimate the effectiveness of gonadotropin-releasing hormone (GnRH) analogues cotreatment in preventing chemotherapy-induced amenorrhea in young breast cancer patients undergoing cyclophosphamide-based chemotherapy. 

METHODS: One hundred hormone-insensitive breast cancer participants (aged 18-40 years) were recruited from two university-affiliated oncology centers in Egypt. Opting for type of cotreatment was based on available timeframe until start of chemotherapy. Fifty women ready for early chemotherapy were randomized to receive either chemotherapy alone (arm I) or chemotherapy after downregulation (estradiol less than 50 pg/mL) by GnRH antagonist and agonist (arm II). Then, GnRH antagonist was discontinued and agonist was continued until the end of chemotherapy. When chemotherapy was to start later than 10 days after study inclusion, 50 women were randomized to receive either chemotherapy alone (arm III) or chemotherapy after downregulation with GnRH agonist (arm IV). Resumption of menstruation at 12 months after end of chemotherapy was the primary outcome. Postchemotherapy hormonal and ultrasound changes were secondary outcomes. 

RESULTS: Twelve months after termination of chemotherapy, there were no differences in menstruation resumption rates between GnRH-treated patients and control group individuals in either early (80% in arms I and II, risk ratio 1, 95% confidence interval 0.7-.32; P=1.00) or delayed chemotherapy groups (80% and 84% in arms III and IV, risk ratio 0.95, 95% confidence interval 0.73-1.235; P=.71). There were no differences in hormonal and ultrasound markers between GnRH analogue users and control group individuals. The use of GnRH analogue cotreatment did not predict independently the odds of menstruating at 12 months. 

CONCLUSION: GnRH analogue cotreatment does not offer a significant protective effect on ovarian function in patients treated by cyclophosphamide-based chemotherapy. CLINICAL TRIAL REGISTRATION:: Australian New Zealand Clinical Trials Registry. www.anzctr.org.au, ACTRN12609001059257. LEVEL OF EVIDENCE:: I.

Sunday, December 16, 2012

Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

Current status and implications of microRNAs in ovarian cancer diagnosis and therapy

Ovarian cancer is the fifth most common cancer among women and causes more deaths than any other type of female reproductive cancer. Currently, treatment of ovarian cancer is based on the combination of surgery and chemotherapy.

While recurrent ovarian cancer responds to additional chemotherapy treatments, the progression-free interval becomes shorter after each cycle, as chemo-resistance increases until the disease becomes incurable. There is, therefore, a strong need for prognostic and predictive markers to help optimize and personalize treatment in order to improve the outcome of ovarian cancer.

An increasing number of studies indicate an essential role for microRNAs in ovarian cancer progression and chemo-resistance. MicroRNAs (miRNAs) are small endogenous non-coding RNAs (~22bp) which are frequently dysregulated in cancer.

Typically, miRNAs are involved in crucial biological processes, including development, differentiation, apoptosis and proliferation. Two families of miRNAs, miR-200 and let-7, are frequently dysregulated in ovarian cancer and have been associated with poor prognosis.

Both have been implicated in the regulation of epithelial-to-mesenchymal transition, a cellular transition associated with tumor aggressiveness, tumor invasion and chemo-resistance. Moreover, miRNAs also have possible implications for improving cancer diagnosis; for example miR-200 family, let-7 family, miR-21 and miR-214 may be useful in diagnostic tests to help detect ovarian cancer at an early stage.

Additionally, the use of multiple target O-modified antagomirs (MTG-AMO) to inhibit oncogenic miRNAs and miRNA replacement therapy for tumor suppressor miRNAs are essential tools for miRNA based cancer therapeutics. In this review we describe the current status of the role miRNAs play in ovarian cancer and focus on the possibilities of microRNA-based therapies and the use of microRNAs as diagnostic tools.

Author: Mohd Saif ZamanDiane M MaherSheema KhanMeena JaggiSubhash C Chauhan
Credits/Source: Journal of Ovarian Research 2012, 5:44


7th Space Interactive

Sunday, November 18, 2012

Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2


Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2


2011




Abstract


Platinum-based chemotherapy, with cytoreductive surgery, is the cornerstone of treatment of advanced ovarian cancer, however acquired drug resistance is a major clinical obstacle. It has been proposed that subpopulations of tumour cells with stem-cell like properties, such as so-called side populations (SP) which over-express ABC drug-transporters, can sustain the growth of drug resistant tumour cells, leading to tumour recurrence following chemotherapy. The histone methyltransferase EZH2 is a key component of the Polycomb Repressive Complex 2 (PRC2) required for maintenance of a stem cell state and overexpression has been implicated in drug resistance and shorter survival of ovarian cancer patients. We observe higher percentage SP in ascites from patients that have relapsed following chemotherapy compared to chemonaive patients, consistent with selection for this subpopulation during platinum-based chemotherapy. Furthermore, ABCB1 (P-glycoprotein) and EZH2 are consistently over-expressed in SP compared to non-SP from patients’ tumour cells. SiRNA knockdown of EZH2 leads to loss of SP in ovarian tumour models, reduced anchorage-independent growth and reduced tumour growth in vivo. Together these data support a key role for EZH2 in the maintenance of a drug-resistant tumour-sustaining subpopulation of cells in ovarian cancers undergoing chemotherapy. As such, EZH2 is an important target for anticancer drug development.



Monday, November 12, 2012

Ovarian Cancer, Version 3.2012.


Ovarian Cancer, Version 3.2012.


Nov 2012


Source

From 1City of Hope Comprehensive Cancer Center; 2University of Alabama at Birmingham Comprehensive Cancer Center; 3The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; 4Fox Chase Cancer Center; 5Dana-Farber/Brigham and Women's Cancer Center; 6UCSF Helen Diller Family Comprehensive Cancer Center; 7The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 8Vanderbilt-IngramCancer Center; 9The University of Texas MD Anderson Cancer Center; 10University of Washington Medical Center/SeattleCancer Care Alliance; 11Moffitt Cancer Center; 12Duke Cancer Institute; 13University of Michigan Comprehensive CancerCenter; 14Roswell Park Cancer Institute; 15Massachusetts General Hospital Cancer Center; 16UNMC Eppley CancerCenter at The Nebraska Medical Center; 17Memorial Sloan-Kettering Cancer Center; 18St. Jude Children's Research Hospital/University of Tennessee Cancer Institute; 19Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 20Stanford Cancer Institute; 21Huntsman Cancer Institute at the University of Utah; and 22National Comprehensive Cancer Network.

Abstract


These NCCN Guidelines Insights focus on the major updates for the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer by describing how and why the new recommendations were made. The 6 update topics were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials, and include: 1) screening, 2) diagnostic tests for assessing pelvic masses, 3) primary treatment using neoadjuvant chemotherapy, 4) primary adjuvant treatment using bevacizumab in combination with chemotherapy, 5) therapy for recurrent disease, and 6) management of drug/hypersensitivity reactions. These NCCN Guidelines Insights also discuss why some recommendations were not made (eg, panel members did not feel the new data warranted changing the guideline). See "Updates" in the NCCN Guidelines for Ovarian Cancer for a complete list of all the recent revisions.

Tuesday, November 6, 2012

What is ovarian cancer and how can you fight it?

What is ovarian cancer and how can you fight it?


According to a study conducted by the World Health Organisation, one in every 12 women in urban India will, potentially, suffer from cancer. 


The five main types of cancer that can affect a woman's organs are cervical, ovarian, uterine, vaginal and vulvar. Among these, breast cancer is a leading cause behind the maximum number of cancer-related female deaths in India, closely followed by ovarian cancer.
Ovarian cancer is more dangerous than any other cancers because the survival rate of a woman suffering from ovarian cancer is far lower than any other cancer that affects women, as it is difficult to detect in the early stages. Today, we take a look at this slow killer and tell you how you can prevent it. 

What is ovarian cancer? 

According to ovariancancer.org, 'Ovarian cancer is a growth of abnormal malignant cells that begins in the ovaries.'

Ovarian cancer can be of two types: Benign (non-cancerous) and malignant (cancerous).

The only difference between the two is that in its benign form, the tumors do notspread to the other parts of the body; whereas in its malignant form, the tumor spreads to other parts of the body through the bloodstream. 


What are its symptoms? 

Early stages may not show many symptoms, but as the cancer grows there may be symptoms like:-

Pain in the abdomen, pelvis or legs

Swollen abdomen

Nausea, diarrhea or constipation

Feeling tired all the time

Difficulty in eating 


Weight loss or weight gain

Fatigue

Pain during intercourse

Frequent urination

The above symptoms are very common and may be associated with normal health worries, but if the problem persists over a longer duration, take medical assistance quickly as negligence may prove fatal. 


Is ovarian cancer treatable? 

Ovarian cancer is treatable, if detected in the early stages. If diagnosed at the right time, medical treatment can prevent the tumor/s from spreading to different parts of the body.

Depending on the stages of the cancer, your doctor may suggest a combination of treatments. Mostly a surgery is carried out, followed by chemotherapy. The various treatments are as follows. 


Surgery 

A surgery is carried out, both to diagnose ovarian cancer and to treat it as well. Tissue is removed from the ovary to examine it. Once examined, the main goal of the surgeon is to remove the tumor completely. To prevent the spreading of the tumor, your doctor may remove ovaries and the surrounding tissues. A second surgery may also be carried out after all other treatments. 

Chemotherapy 

This treatment uses drugs to slow down the growth of cancer and reduce the chances of reoccurrence. 

Radiation therapy 

Women with ovarian cancer are mostly treated with external radiation. The treatment uses a high energy X-ray to kill all the cancer causing cells. 

Risks factors 

The fact is that ALL women, are at a risk of developing ovarian cancer, simply because they are women. Therefore all women's should check the signs and prevent it from happening. Besides this, some other risk factors are 

Family history 

According to the American Cancer Society, 10% of ovarian cancer can be hereditary. Having a family history of ovarian, breast or colorectal cancer increases the chances of ovarian cancer in women. The possibility of developing ovarian cancer is due to the mutations in BRCA1 or BRCA2 genes. The younger you are or the family member who got diagnosed with the disease, the higher are your chances of developing ovarian cancer. 

Post menopausal 

Most of the ovarian cancer cases have been diagnosed in women who have crossed the age of 55-60 or after a women has entered menopause. 

Overweight 

According to Dr. Sheetal, there is a high chance of developing ovarian cancer if you are obese. The American Cancer Society has also correlated a higher rate of ovarian cancer in obese women. 

Infertility 

Women who have never been pregnant or have used some sort of drugs to achieve pregnancy seem to have a higher risk of developing ovarian cancer. 

What can one do to prevent ovarian cancer? 

The appropriate medicine has still not been discovered, but here are a few tips to reduce one's risk of developing ovarian cancer. 

Oral contraception 

Consumption of birth control pills for more than 5 years can reduce the risk of developing ovarian cancer. The longer the birth controls pills are used, the lesser are the chances of developing ovarian cancer. However, you must consult your doctor before assuming that the pills you take will prevent ovarian cancer, especially if you take them regularly. 

Breastfeeding and pregnancy 

Bearing children before the age of 28 can reduce the risk of ovarian cancer. Breastfeeding may also decrease one's risk of developing ovarian cancer. 
Surgical prevention 

Women who are at a higher risk of developing ovarian cancer due to genetics or who are outside of their reproductive stages can opt for surgical preventions. The various surgical preventions such as tubal ligation and oophorectomy can greatly reduce the risk of developing ovarian cancer.Read more Personal Health, Diet & Fitness stories on www.healthmeup.com

Saturday, November 3, 2012

Roche receives EC approval for treatment of platinum-sensitive ovarian cancer


Roche receives EC approval for treatment of platinum-sensitive ovarian cancer


Comtex News Network

Nov 02, 2012 (Datamonitor via COMTEX) -- Roche Holding AG has received European Commission, or EC, approval for Avastin in combination with standard chemotherapy, carboplatin and gemcitabine, as a treatment for women with first recurrence of platinum-sensitive ovarian cancer.
Avastin is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. The additional approval of the medicine is important for women with ovarian cancer who are now able to receive Avastin in combination with chemotherapy once their disease returns.
Patients are said to have 'platinum-sensitive' disease if their ovarian cancer returns more than 6 months after completion of platinum-based chemotherapy.
This approval was based on data from the Phase III OCEANS study which showed that women with recurrent, platinum-sensitive ovarian cancer who received Avastin in combination with chemotherapy lived significantly longer without their disease getting worse (progression-free survival) compared to those who received chemotherapy alone (HR=0.48; p<0.0001).
Ovarian cancer is associated with high concentrations of vascular endothelial growth factor (VEGF), a protein associated with tumor growth and spread. Avastin is an antibody that precisely targets and inhibits VEGF for tumor control, the company said.
"This EU approval of Avastin is an important advance for women with recurrent ovarian cancer because very few treatment advances have been made in over a decade for patients with the disease," said Hal Barron, Roche's chief medical officer and head of global product development.
http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon 

Wednesday, October 24, 2012

Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening.


Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening.


Oct 2012

Abstract


BACKGROUND: Ovarian cancer stem cells are characterized by self-renewal capacity, ability to differentiate into distinct lineages, as well as higher invasiveness and resistance to many anticancer agents. Since they may be responsible for the recurrence of ovarian cancer after initial response to chemotherapy, development of new therapies targeting this special cellular subpopulation embedded within bulk ovarian cancers is warranted.

METHODS:

A high-throughput screening (HTS) campaign was performed with 825 compounds from the Mechanistic Set chemical library [Developmental Therapeutics Program (DTP)/National Cancer Institute (NCI)] against ovarian cancer stem-like cells (CSC) using a resazurin-based cell cytotoxicity assay. Identified sets of active compounds were projected onto self-organizing maps to identify their putative cellular response groups.

RESULTS:

From 793 screening compounds with evaluable data, 158 were found to have significant inhibitory effects onovarian CSC. Computational analysis indicates that the majority of these compounds are associated with mitotic cellular responses.

CONCLUSIONS:

Our HTS has uncovered a number of candidate compounds that may, after further testing, prove effective in targeting both ovarian CSC and their more differentiated progeny.

Advanced line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer.


Advanced line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer.


Source

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba Israel, affiliated with the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: ilan.bruchim@gmail.com.

Abstract


OBJECTIVE:

To explore the pattern of chemotherapy (beyond the second-line) used to treat patients with recurrent epithelial ovarian cancer (including primary peritoneal carcinoma).

STUDY DESIGN:

This retrospective study included 156 patients with recurrent epithelial ovarian cancer and primary peritoneal carcinoma who were treated in the Gynecologic Oncologic Department at Meir Medical Center between November 1995 and December 2003. Clinical characteristics and data regarding the surgery, chemotherapy, and response to treatment were abstracted from the patients' medical records to determine patient response to advanced lines of chemotherapy for recurrent epithelial ovarian cancer.

RESULTS:

Of the 156 patients, 63 (40%) were treated beyond second-line chemotherapy. Clinical response to third-line chemotherapy was 11.9% (6.8% had complete clinical response and 5.1% partial clinical response) and 3.4% had stable disease. A total of 17% did not show immediate progression, with a median progression free-interval of 1.5 months. A drastic decline in clinical response rates was shown beyond third-line chemotherapy. Any response to treatment in more advanced lines was consistently under 5%.

CONCLUSION:

These results imply that advanced lines of chemotherapy are associated with low response rates, although a small percentage of patients showed some clinical response or remained with stable disease at the end of treatment. Along with patient preferences, the advantages and disadvantages of continued therapy should be considered, for the side effects of each treatment cannot be overlooked.